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Abstract: Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with
either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there
are excellent long-term data for intravenous application, similar data regarding subcutaneous adminis-
tration are lacking. We therefore analyzed the long-term outcome of 3 prospective multicenter clinical
trials on subcutaneous cladribine performed by the Swiss Group for Clinical Cancer Research (SAKK),
which recruited 221 patients with classical HCL between 1993 and 2005. Median overall survival from
start of treatment was not reached. Pretreatment anemia, higher Eastern Cooperative Oncology Group
score, and higher age were associated with poorer overall survival in multivariable analysis, whereas early
progression at 24 and 36 months had no significant impact on overall survival. Second-line treatment was
necessary in 53 (23.7%) patients after a median of 5 (range, 0.2-20.4) years, and first retreatment was
mainly monotherapy with cladribine (66%) or rituximab (15.1%) or a combination of these drugs (15.1%).
A total of 44 (19.9%) patients developed second primary malignancies with a median time to occurrence
of 5.7 (range, 0.01-17.5) years. Second primary malignancies were the main cause for death (14; 27.5%).
Compared with a matched normal Swiss population, the incidence of second primary malignancies was
not increased. However, survival of patients with HCL was slightly inferior by comparison (P = .036). In
conclusion, the outcome of HCL patients treated with subcutaneous cladribine is excellent, and in most
patients, 1 cycle of subcutaneous cladribine is sufficient for long-term disease control.
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Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with
either intravenous or subcutaneous cladribine generally leads to long-lasting remissions.
Although there are excellent long-term data for intravenous application, similar data
regarding subcutaneous administration are lacking. We therefore analyzed the long-term
outcome of 3 prospective multicenter clinical trials on subcutaneous cladribine
performed by the Swiss Group for Clinical Cancer Research (SAKK), which recruited 221
patients with classical HCL between 1993 and 2005. Median overall survival from start of
treatment was not reached. Pretreatment anemia, higher Eastern Cooperative Oncology
Group score, and higher age were associated with poorer overall survival in multivariable
analysis, whereas early progression at 24 and 36 months had no significant impact on
overall survival. Second-line treatment was necessary in 53 (23.7%) patients after
a median of 5 (range, 0.2-20.4) years, and first retreatment was mainly monotherapy with
cladribine (66%) or rituximab (15.1%) or a combination of these drugs (15.1%). A total of
44 (19.9%) patients developed second primary malignancies with a median time to
occurrence of 5.7 (range, 0.01-17.5) years. Second primary malignancies were the main
cause for death (14; 27.5%). Compared with a matched normal Swiss population, the
incidence of second primary malignancies was not increased. However, survival of patients
with HCL was slightly inferior by comparison (P 5 .036). In conclusion, the outcome of
HCL patients treated with subcutaneous cladribine is excellent, and in most patients,
1 cycle of subcutaneous cladribine is sufficient for long-term disease control.
Introduction
Hairy cell leukemia (HCL) is a rare indolent mature B-lymphoid neoplasm with an incidence between 2.9
and 4.7 per million people per year.1,2 It is characterized by various degrees of pancytopenia, particularly
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monocytopenia, with typical hairy cells in the peripheral blood or
bone marrow in combination with splenomegaly, hepatomegaly,
and rarely lymphadenopathy. Over the last decades, the excellent
responsiveness to interferon-a and the 2 purine analogs pentostatin
and cladribine has substantially improved survival rates, reaching
almost normal survival.3-7 Despite the success of purine analog
treatment, significant side effects such as infections and secondary
malignancies caused by profound and long-lasting immunosup-
pression are still a matter of concern.8
Continuous intravenous application of cladribine has been applied
in most clinical trials and is still used in many centers as first-line
treatment of patients with HCL. However, although the plasma half-
life of cladribine is short, the drug accumulates within leukemic cells
and has a longer intracellular half-life, making the subcutaneous
application feasible.9,10 This is an attractive option facilitating
outpatient treatment of patients in good health. In the 1990s, the
Swiss Group for Clinical Cancer Research (SAKK) developed
several trials looking at the outcome of subcutaneous cladribine,
showing feasibility using a 5-day schedule. However, long-term
follow-up data are mostly based on patients after intravenous
cladribine administration in single-center cohorts.7,11-13 Only
1 population-based study with 85 patients analyzed the long-term
effect of mainly subcutaneous applied cladribine, suggesting equal
long-term efficacy.14 We therefore analyzed the long-term outcome
in a large population of patients with classical HCL based on 3
prospective, multicenter SAKK trials with subcutaneous cladribine,
and we compared the results with a matched normal Swiss
population.
Materials and methods
Patients and trial design
Between 1993 and 2005, the SAKK performed 3 subsequent
prospective studies analyzing the feasibility of subcutaneous cladribine
treatment (Litak 10, solution for subcutaneous injection or in-
travenous infusion; Lipomed AG) in patients with HCL (SAKK 32/
93, SAKK 32/95, SAKK 32/98). Rationale, regimens, and detailed
short-term results are published elsewhere.15-17 The current long-
term follow-up analysis is based on the patients included in these 3
studies. Within the clinical trials, all patients were either subject to
lifelong follow-up (SAKK 32/93) or until progression, relapse, or
death (SAKK 32/95 and SAKK 32/98). All trials were approved by
the ethical committees of the Swiss centers. Response was
assessed by peripheral blood and bone marrow at 10 weeks. The
consensus criteria, published in 1987, applied for remission
definition.18 A total of 237 patients were accrued in the 3 trials.
Four patients were in 2 of these trials, and 12 patients needed to be
excluded because of nonclassical HCL phenotype. Therefore, 221
patients were analyzed. Ninety-two (41.2%) patients had their last
follow-up information before 31 May 2013 within the initial study
protocol, which is more than 5 years before the data cutoff of 31
May 2018. However, using an additional questionnaire, follow-up
data were obtained from 87% of the patients still alive with a cutoff
data of 31 January 2018.
Treatment schedules
Treatment algorithms in the studies were as follows: (1) 5 days of
subcutaneous cladribine 0.14 mg/kg followed by a maximum of 2
cycles of 7 days of intravenous cladribine 0.1 mg/kg in case of minor
response or no response (SAKK 32/93); (2) single shot of
subcutaneous cladribine 0.25 mg/kg followed by a maximum of 2
cycles of subcutaneous cladribine 0.14 mg/kg for 5 days in case of
minor response, no response, or relapse (SAKK 32/95); and (3) 5
consecutive days of subcutaneous cladribine 0.14 mg/kg vs the
same dose in 5 weekly applications (SAKK 32/98). SAKK 32/93
included 63, SAKK 32/95 included 74, and SAKK 32/98 included
100 patients. In all studies, assessment of early response was at
10 weeks after treatment initiation. In the few non–complete
response/partial response (CR/PR) patients, additional treatment
was administered as outlined in earlier publications.15-17 Response
criteria were similar to those published in the consensus guidelines
by Grever in 2017, and the same criteria were applied in all 3
studies.8 Of note, response in the bone marrow biopsy was
assessed conventionally and by tartrate resistant acid phosphatase
(TRAP) staining. All protocols recommended long-term follow-up
every 6 months.
Statistics
Baseline characteristics are shown as median with ranges and
absolute numbers with percentages as appropriate. Overall survival
(OS) is defined from the start of treatment until death, whereas
follow-up time is defined from registration until death or last date
known alive. In case that the start of OS is different, this will be
specified. OS and follow-up time were assessed by Kaplan-Meier
and reverse Kaplan-Meier method, respectively. Prognostic factors
were identified by univariable and multivariable Cox regression
analysis and are displayed as hazard ratios (HRs), Wald 95%
confidence interval (CI), and P values. To identify the optimal
cutoff of numerical prognostic factors, P values were adjusted
according to Lausen et al.19 Progression of disease at 24 months
(POD24) and 36 months (POD36) was defined as experiencing
HCL progression within 24 or 36 months from treatment start,
respectively. Survival analysis according to POD24 and POD36
was calculated for patients with events (progression or death)
within 24 or 36 months or for those with at least 24 or 36 months of
follow-up in the case where no POD24- or POD36-defining event
was reported. OS was compared with age-adjusted survival of the
normal Swiss population. Absolute survival of the study cohort was
compared with expected survival of age-, sex-, and period-matched
groups of the general population using the life-table approach.
Expected survival was estimated using the Ederer II method.20 The
relative risk of second primary malignancies (except nonmelanotic
skin cancer, which was not reported to the registry) was quantified
by comparing the observed number of cancers in the study cohort
with the expected number of cancers, based on age-, sex-, and
period-specific rates of the Swiss population provided by the National
Institute for Cancer Epidemiology and Registration (indirect stan-
dardization). The time to next treatment was calculated from the
beginning of the first-line treatment to the beginning of subsequent
treatment. R 3.5.3 (R Core Team; www.r-project.org) and SAS 9.4
(SAS Institute; www.sas.com) were used to perform the analyses.
Results
Baseline characteristics
Baseline characteristics are shown in Table 1. The median age of
patients was 54 years (range, 21-96 years) at the time of diagnosis
and 55 years (range, 21-96 years) at study entry. The median time
from diagnosis to study entry was short (0.09 years; range, 0-19.0





































































































years). At the time of data analysis, the median follow-up time from
study registration was 12.6 years (95% CI, 10.1-14.6) in surviving
patients. Most patients were male (170 of 221, 76.9%), were
previously untreated (162 of 221, 73.3%), and had a good
Eastern Cooperative Oncology Group (ECOG) performance status
(0 or 1: 206 of 221, 93.2%). Two thirds of the patients had
splenomegaly at study entry (147, 66.5%), whereas only a minority
had hepatomegaly (28, 12.7%) or lymphadenopathy (31, 14.0%).
Median peripheral blood values showed modest anemia (median
hemoglobin, 11.4 g/dL), thrombocytopenia (median, 78 3 109/L),
leukopenia (median, 2.73 109/L), and monocytopenia (median, 0.1
3 109/L). Treatment of HCL before study inclusion consisted of
interferon (51, 23.1%) or splenectomy (22, 10%). All patients were
purine analog naı̈ve at inclusion. Twenty-one patients had received
more than 1 previous therapy before study entry, explaining why the
number of treatments exceeds the number of pretreated patients.
At the time of study entry, all patients had treatment indications
caused by peripheral cytopenias and/or organomegaly. Treatment
of 147 patients in the 32/93 and 32/98 studies was equal
except of a weekly administration of the same dose of cladribine
in 50 patients in the 32/98 study. The major difference was the
schedule of the 32/95 study. However, 58 of those patients were
in non-CR/PR at week 10 and had to be treated with a standard
cycle of 0.14 mg/kg (subcutaneous) on 5 consecutive days per
protocol.16 Therefore, a total of 205 patients or 93%were treated in
quite homogenous way.
Overall survival
Fifty-one patients have died. The median OS was not reached, but
the median OS from diagnosis was 31.6 (95%CI, 31.6-37.8) years.
The OS probability at 10 and 20 years was 80.0% (95%CI, 74.3%-
86.0%) and 66.9% (95% CI, 58.4%-76.6%), respectively (Figure 1).
The principal causes of death were second tumors (14, 27.5%),
cardiovascular causes (10, 19.6%), HCL-related causes (7, 13.7%),
infections (6, 11.8%), and various other causes (4, 7.8%). In 10
patients, the cause of death was not known. Relative survival of the
HCL patients was compared with the age- and sex-adjusted Swiss
population (Figure 2). With an observation time of 15 years, patients
with HCL showed a slightly inferior OS compared with the age-
matched population (P 5 .036).
Initial response, prognostic factors, and retreatment
The response to the purine analog treatment was assessed in 218
patients after the first treatment at day 71. The overall response rate
was 88.0%, with 48.6% complete and 39.4% partial remissions.
Early mortality within 6 months after treatment with subcutaneous
cladribine was observed in 8 of 221 patients (3.6%) and was
directly linked to the treatment in only 3 cases, whereas 3 deaths
were related to cancer and the remaining 2 to cardiovascular
causes. None of the patients with treatment-related death were
splenectomized.
In a univariable Cox regression analysis regarding OS, ECOG
performance status (1 vs 0: HR, 2.79; 95% CI, 1.56-5.01; P ,
.001; 2 vs 0: HR, 3.53; 95% CI, 1.43-8.67; P , .001), age at
treatment start (HR, 1.12; 95% CI, 1.09-1.15; P, .001), and lower
hemoglobin level as a continuous variable (HR, 0.87; 95% CI, 0.78-
0.97; P 5 .013) were associated with impaired OS (Table 2). The
optimal hemoglobin cutoff level was established as 10.2 g/dL (HR,
0.4; 95%CI, 0.2-0.7; Pcorrected, .031), whereas the optimal cutoff for
age at start of treatment was 60.3 (HR, 11.8; 95% CI, 5.5-25.1;
Pcorrected, ,.001). In the multivariable analysis, ECOG performance
status, hemoglobin and age remained significant.
Remission status (PR vs CR) within 71 days after treatment was
not significantly predictive for OS (HR, 1.46; 95% CI, 0.73-2.94;
P5 .284). There was a trend to earlier retreatment in patients in PR.
Early progression of disease after 24 months (POD24) occurred
in 33 patients and after 36 months (POD36) in 46 patients.
As displayed in Figure 3, neither POD24 (HR, 1.43; 95% CI, 0.68-
3.02; P 5 .351) nor POD36 (HR, 1.10; 95% CI, 0.52-2.31;
P 5 .803) was discriminative for OS.
Type and criteria for late retreatment were up to the discretion of the
treating physician. Retreatment was initiated in 53 (24.0%) patients




At diagnosis 54.2 (20.7, 96.1)









Stage at study entry
Untreated 162 (73.3)
Relapsed 39 (17.8)












Hemoglobin, g/dL 11.4 (4.5, 16.3)
Platelets, 3109/L 78 (4.3, 318.0)
Leukocytes, 3109/L 2.7 (0.2-41.1)
Monocytes, 3109/L 0.1 (0.0, 12.4)
LDH, U/L 323.5 (81.0, 792.0)
LDH, lactate dehydrogenase.
*Number (%), unless otherwise indicated.
†Median (min, max).





































































































after a median of 5 (range, 0.2-20.4) years. First retreatment was
mainly cladribine (35, 66.0%), rituximab (8, 15.1%), or cladribine
and rituximab (8, 15.1%). Twenty-two patients (9.8%) required more
than 1 retreatment. Patients achieving a PR after initial treatment
were more likely to receive a rituximab-containing regimen compared
with patients relapsed after CR (14% vs 8%).
Second primary malignancies
A total of 44 (19.9%) patients developed second primary malignan-
cies from the start of treatment with a mean time to occurrence of
5.7 (range, 0.01-17.5) years. Mortality from second cancers was 14
of 44 (31.8%) with a broad variety of tumor types. There was no
significant difference of the incidence of second primary malignan-
cies compared with a matched normal population (standardized
incidence ratio, 1.24; 95% CI, 0.89-1.74; P 5 .206). Most of the
second primary malignancies were of nonhematologic origin (36,
85.7%), and most were skin cancer (13, 30.9%), followed by
prostate cancer (8, 19.0%) and colorectal cancer (19.0%; Table 3).
Eight patients (19%) developed hematologic second primary
malignancies with a predominance of B-lymphoid neoplasms. Only
1 case of acute myeloid leukemia was observed.
Discussion
Our study shows excellent long-term outcome of patients with HCL
treated with subcutaneous cladribine. Median OS from diagnosis
was more than 31 years. Compared with a matched healthy Swiss
population, survival was only slightly inferior. For most patients,
1 cycle of subcutaneous cladribine was sufficient for long-term
disease control. Interestingly, early disease progression was not
0
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Figure 1. OS of patients with HCL treated with
subcutaneous cladribine. The median OS was not
reached. The survival probability at 10 and 20 years was
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Figure 2. Relative survival of patients with HCL
compared with a matched Swiss population. Abso-
lute survival was calculated from the start of treatment
and was compared with expected survival of an age-,
sex- and period-matched Swiss general population using
the life-table approach. The blue line represents the
expected cumulative survival of the matched normal pop-
ulation, the black line represents the observed cumulative
survival in patients with HCL, and the hashed lines repre-
sent the 95% CI of the cumulative observed survival.
Patient with HCL showed a slight statistically significant
inferior OS compared with the normal population
(P 5 .036).





































































































associated with an impaired OS. Hemoglobin levels, age, and
performance status were associated with poorer survival and
may help to predict outcome in patients receiving subcutaneous
cladribine treatment. Second primary malignancies occurred in
19.9% of the patients; however, they were not more frequent
compared with the age-matched normal population. Nevertheless,
physicians should pay attention to second primary malignancies
and patients should undergo lifelong follow-up.
Several published studies have shown excellent long-term survival
after initial treatment with different types and regimens of purine
analogs. A large long-term follow-up analysis of 233 patients mostly
treated with pentostatin showed a 15-year survival of 78%.21 In
a single-center study, 44 patients received intravenous cladribine as
continuous infusion over 7 days with a 12-year OS of 79%.11
Chadha and colleagues published their experience in 86 HCL
patients treated with intravenous cladribine, showing a median 12-
year OS of 86%.22 Eighty-eight younger patients (,40 years of
age) with a follow-up of .19 years treated with intravenous
cladribine had a median OS of 251 months.12 The only publication
looking at subcutaneous administration of cladribine was based on
Swedish registry data and found a 15-year OS of .80% in 85
younger patients.14 However, most publications are based on
retrospective single-center analyses using a variety of different
drugs and regimens.23 Thus, our study is the largest analysis of HCL
patients treated with subcutaneous cladribine based on 3
multicenter prospective studies using a uniform treatment approach
for all patients. The 10-year OS of 80% is comparable with other
studies using intravenous treatment, although our population is
slightly older than other study populations.24
We compared OS to an age- and sex-matched Swiss population.
Survival was slightly inferior to the normal population. However,
even with longer follow-up, the curves do not diverge. This suggests
that HCL-related mortality and the mortality from second primary
malignancies in patients with HCL treated with subcutaneous
cladribine do not impact survival more than in a normal population.
Moreover, HCL-related mortality will likely be further reduced
because of availability of treatment options, such as regular use
of rituximab, BRAF inhibitors, or CD22 antagonists.25
The complete remission rate in our cohort (CR, 48.6%; PR, 39.4%)
was lower compared with other studies reporting a range between
70% and 100%. This might be explained by the early time point of
the bone marrow assessment in the 3 trials (mainly day 71). In the
literature, CR rates increase with time from 80%22 if assessed after
3 to 4 months to almost 100%11,26 after 6 months. Indeed,
response improvement can be observed up to 9 months.27
Unfortunately, in many publications, the time point and method of
response assessment are not clearly stated, making comparison of
CR rates among different studies difficult; therefore, differences
should be interpreted with caution. Current guidelines recommend
response assessment not earlier than 4 to 6 months after treatment
with purine analogs.8 Second, although many studies determined
CR based on conventional hematoxylin and eosin staining, in the 3
SAKK studies, remission assessment was based on staining for
TRAP. Histochemical positivity of remaining hairy cells facilitates
their detection and increases the sensitivity of the method. Hence,
some complete remissions by HE staining might have been
assessed as partial remissions using the TRAP staining potentially
lowering the rate of CR in our study.11,28 Third, comparison of the
CR rates between studies using cladribine or pentostatin might be
misleading because pentostatin is generally given until best
response, whereas cladribine is given as a fixed dose potentially
resulting in lower CR rates when assessed early.29 Last, rituximab
was used more frequently in PR than in CR patients. Rituximab is
known to improve response rate30 and might have counteracted
some of the inferior prognosis of patients in PR. It is therefore
recommended to take the addition of rituximab into consideration in
patient needing retreatment to delay further relapses.31 Reassur-
ingly, long-term OS of our patient population was excellent and
comparable to studies using intravenous cladribine, making it
unlikely that the lower CR rates reflect real differences in the
response rates.
Because patients relapsing may remain stable over a long period of
time, we analyzed time to retreatment as a clinically relevant
parameter. In total, 24% of the study population required retreat-
ment after a median of 5 years, which was in line with earlier studies.
We analyzed factors other than treatment that might influence
outcome in our population. Earlier studies established a correlation
of overall and disease-free survival with anemia and thrombocyto-
penia,7 and newer data found a correlation with IGHV4-34
molecular variants32 or telomer length.33 In our study, only conven-
tional pretreatment variables such as clinical data and standard blood
values were available. There was a correlation between anemia,
age, ECOG status, and survival in line with earlier findings
correlating anemia and thrombocytopenia with lower disease-
free survival.7 Anemia does not seem to impact on early mortality
but rather on long-term survival.
Early progression of disease was recently introduced in several low-
grade lymphomas as a dynamic marker for the aggressiveness of
the disease. POD24 was able to delimit a group with poorer OS in
follicular lymphoma and marginal zone lymphoma.34-36 In contrast,
in our cohort of patients with classical HCL, neither POD24 nor
POD36 was associated with poorer OS. We speculate that this
difference might be explained by the different biology of these low-
grade lymphomas. Although in follicular andmarginal zone lymphoma,
early progression most likely selects patients with a disease in
transformation, this does not occur in patients with HCL.
Although our study focused on long-term efficacy and toxicity, early
side effects are still a matter of concern, and patients with active
Table 2. Prognostic factors for overall survival
Univariable Multivariable
HR 95% CI P HR 95% CI P
Log2 (platelets) 0.91 0.89-1.20 .506 0.88 0.63-1.23 .462
Hemoglobin 0.87 0.78-0.97 .013 0.86 0.75-1.00 .048
Log2 (leukocytes) 1.18 0.91-1.53 .202 1.07 0.86-1.32 .564
Log2 (LDH) 1.39 0.83-2.32 .207 1.03 0.62-1.69 .915
Age at treatment start 1.12 1.09-1.15 ,.001 1.12 1.09-1.15 ,.001
ECOG
0 1.00 1.00
1 2.79 1.56-5.01 ,.001 2.11 1.12-4.00 .022
2 3.53 1.43-8.67 .006 1.29 0.46-3.60 .625
LDH, lactate dehydrogenase.





































































































infections should not be treated with cladribine.8However, the way of
administration does not seem to have a major impact on early toxicity
despite missing data based on randomized studies.9,11,15,37,38 In
a pooled analysis of all 3 studies, we found an overall infection rate
according to World Health Organization grading of 18.5% grade 1,
9.3% grade 2, 6% grade 3, and 5.6% grade 4 (supplemental Data).
In addition, weekly vs daily schedules were of no benefit when
compared in a randomized fashion.17,39 In summary, no treatment
schedule shows clear superiority or inferiority in early toxicity.
Evaluation of long-term toxicitiy is therefore of further importance to
have the complete basis to decide on the most effective, safe, and
convenient initial treatment schedule.
The overall incidence of second primary tumors in patients with
HCL who had received subcutaneous cladribine was 19.9%
without a clear predominance of a specific tumor entity and without
increase of therapy-related myeloid malignancies. This is in line with
epidemiologic data that found a 24% incidence of second cancers
in patients with HCL.40 Likewise, we did not observe a statistically
significant difference of these second primary malignancies (non-
melanotic skin cancers are excluded) compared with the incidence
of primary ones in a normal matched Swiss population. In the
literature, the association between HCL treatment and second
primary malignancies remains controversial. Although several studies
showed an increased rate of second primary malignancies,28,40-42
others could not find a difference.7,43 Of note, the largest registry
study provides indirect evidence of higher rates of second primary
malignancies since the introduction of purine analogs.40 Some







































































Figure 3. POD24 and POD36 after treatment of HCL with
subcutaneous cladribine. (A) POD24. (B) POD36. Early
progression of disease after 24 months (POD24) occurred in
33 patients and after 36 months (POD36) in 46 patients.
Neither POD24 (HR, 1.43; 95% CI, 0.68-3.0221; P 5 .351)
nor POD36 (HR, 1.10; 95% CI, 0.52-2.31; P 5 .803) was
discriminative for OS.





































































































is associated with a higher risk of developing second primary
malignancies. In the current analysis, retreatment was infrequent;
therefore, a correlation of the risk for secondary primary malignan-
cies with the total amount of cladribine could not be determined.
Our study has several limitations. Because of the long-term follow-up
and multicenter design, a potential underreporting of second primary
malignancies and retreatment cannot be excluded. However, both
are in line with other studies, making a significant effect rather
unlikely. Second, the different treatment schedules in the 3
clinical studies and the selection of the patients could have had
an impact on the outcome of the patients despite 93% having
a similar treatment schedule. Third, in some of the analyses, the
relatively low number of events might preclude statistically
significant differences.
In summary, subcutaneous cladribine at a dose of 0.14mg/kg per day
on 5 consecutive days is a convenient and effective treatment in HCL,
with excellent long-term survival similar to the normal population.
Even under long-term observation, no differences were observed
compared with the intravenous application with regard to early
progression, OS, and secondary malignancies, ensuring the possi-
bility of starting treatment in an outpatient facility.
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